title: STAT3 mediates resistance of CD44(+)CD24(-/low) breast cancer stem cells to tamoxifen in vitro.
abstract: We sought to determine whether STAT3 mediated tamoxifen resistance of breast cancer stem cells in vitro. The capacities for mammosphere formation and STAT3 expression of CD44(+)CD24(-/low) MCF-7 and MCF-7 were observed. The CD44(+)CD24(-/low) subpopulation ratio and its sensitivity to adriamycin were analyzed in MCF-7 and TAM resistant (TAM-R) cells. Cell cycle, apoptosis, STAT3 and phospho-STAT3 changes were observed after treatment with tamoxifen. Small interference RNA-mediated knockdown of STAT3 in TAM-R cells was also performed. CD44(+)CD24(-/low) MCF-7 showed higher capacities for mammosphere formation and STAT3 expression than total MCF-7. The CD44(+)CD24(-/low) subpopulation was also upregulated in TAM-R cells with less sensitivity to adriamycin than MCF-7. Cell cycle changes, anti-apoptotic effects and STAT3 changes were also found. Meanwhile, the knock-down of STAT3 in TAM-R resulted in an increase in sensitivity to tamoxifen. It is concluded that STAT3 plays an essential role in breast cancer stem cells, which correlated with tamoxifen resistance.
authors.affiliation: Department of Breast Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China;
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Wang
authors.forename: Guozhu
authors.initials: G
authors.lastname: Wang
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhao
authors.forename: Xiaoan
authors.initials: X
authors.lastname: Liu
authors.forename: Qiang
authors.initials: Q
authors.lastname: Ding
authors.forename: Jingping
authors.initials: J
authors.lastname: Shi
authors.forename: Yin
authors.initials: Y
authors.lastname: Ding
authors.forename: Shui
authors.initials: S
authors.lastname: Wang
keywords: STAT3; breast cancer; cancer stem cells; tamoxifen drug resistance
references.citation: Oncogene. 2000 May 4;19(19):2354-62
references.pmid: 10822387
references.citation: J Biol Chem. 2010 Nov 12;285(46):35855-65
references.pmid: 20807764
references.citation: Expert Opin Ther Targets. 2009 Jun;13(6):665-74
references.pmid: 19456271
references.citation: J Natl Cancer Inst. 2008 May 7;100(9):672-9
references.pmid: 18445819
references.citation: Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
references.pmid: 12629218
references.citation: Lancet. 2005 May 14-20;365(9472):1687-717
references.pmid: 15894097
references.citation: J Natl Cancer Inst. 2006 Jul 19;98(14):1011-4
references.pmid: 16849684
references.citation: Science. 1998 Apr 10;280(5361):196
references.pmid: 9565527
references.citation: J Natl Cancer Inst. 2007 Apr 18;99(8):616-27
references.pmid: 17440163
references.citation: J Biol Chem. 2002 May 17;277(20):17397-405
references.pmid: 11859072
references.citation: Breast Cancer Res Treat. 2009 Jul;116(2):225-37
references.pmid: 19418218
references.citation: Cancer Res. 2000 Oct 1;60(19):5395-400
references.pmid: 11034078
references.citation: Breast Cancer Res Treat. 1997 Jun;44(2):123-33
references.pmid: 9232271
references.citation: Science. 1997 Jan 3;275(5296):90-4
references.pmid: 8974401
references.citation: Biopharm Drug Dispos. 1981 Oct-Dec;2(4):381-90
references.pmid: 7317574
references.citation: Int J Cancer. 1991 Oct 21;49(4):616-23
references.pmid: 1680817
references.citation: Eur J Cancer. 2000 May;36(7):845-51
references.pmid: 10785588
references.citation: J Biol Chem. 1998 Jun 26;273(26):16568-75
references.pmid: 9632728
references.citation: PLoS One. 2011;6(6):e20701
references.pmid: 21687668
references.citation: Endocrinology. 2001 Jul;142(7):2776-88
references.pmid: 11415996
references.citation: Nature. 2007 Jan 4;445(7123):111-5
references.pmid: 17122771
references.citation: Pharmacol Ther. 1984;25(2):127-205
references.pmid: 6438654
references.citation: Cell. 1999 Aug 6;98(3):295-303
references.pmid: 10458605
references.citation: J Cell Biochem. 1996 Apr;61(1):9-17
references.pmid: 8726350
references.citation: J Biol Chem. 2008 Jun 20;283(25):17635-51
references.pmid: 18441325
references.citation: Cancer Res. 2005 Jul 15;65(14):6207-19
references.pmid: 16024622
references.citation: Cancer Res. 1997 Mar 1;57(5):978-87
references.pmid: 9041204
references.citation: Breast Cancer Res. 2010;12(3):R31
references.pmid: 20525204
references.citation: Epigenetics. 2011 Apr;6(4):428-39
references.pmid: 21266853
references.citation: Cancer Res. 2000 Nov 1;60(21):5995-6000
references.pmid: 11085519
references.citation: J Natl Cancer Inst. 2007 May 2;99(9):694-705
references.pmid: 17470737
references.citation: J Clin Oncol. 1989 Jun;7(6):803-15
references.pmid: 2654333
references.citation: Breast Cancer Res. 2008;10(2):R25
references.pmid: 18366788
references.citation: Int J Oncol. 2001 Dec;19(6):1155-60
references.pmid: 11713584
references.citation: Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5774-9
references.pmid: 18391223
references.citation: J Clin Invest. 2002 May;109(9):1139-42
references.pmid: 11994401
references.citation: Maturitas. 2006 Jul 20;54(4):327-34
references.pmid: 16806749
references.citation: Clin Biochem. 2003 Jun;36(4):247-53
references.pmid: 12810152
references.citation: Genes Dev. 2003 May 15;17(10):1253-70
references.pmid: 12756227
references.citation: Int J Cancer. 1998 Sep 11;77(6):928-32
references.pmid: 9714066
references.citation: J Cell Biol. 2007 Jan 1;176(1):19-26
references.pmid: 17190790